Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about 'Reasonable and Necessary'? | J Prev Alzheimers Dis;10(3): 342-343, 2023. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about 'Reasonable and Necessary'?

Schneider, L S.

Affiliation

Schneider LS; Lon S. Schneider, MD, Keck School of Medicine of USC, Los Angeles, USA, lschneid@usc.edu.

J Prev Alzheimers Dis ; 10(3): 342-343, 2023.

Article in En | MEDLINE | ID: mdl-37357268

Subject(s)

Alzheimer Disease; Antibodies, Monoclonal, Humanized; Humans; Alzheimer Disease/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J Prev Alzheimers Dis Year: 2023 Document type: Article Country of publication: Switzerland

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J Prev Alzheimers Dis Year: 2023 Document type: Article Country of publication: Switzerland